Open-Label Study of Safety of H1337 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

October 14, 2024

Study Completion Date

October 14, 2024

Conditions

Glaucoma Open-Angle PrimaryOcular Hypertension

Interventions

DRUG

H-1337 1.0%

ophthalmic solution

Trial Locations (1)

Eye Research Foundation Inc., Newport Beach

All Listed Sponsors

lead

D. Western Therapeutics Institute, Inc.

INDUSTRY

NCT06572397 - Open-Label Study of Safety of H1337 in Healthy Volunteers | Biotech Hunter | Biotech Hunter